PARProceedings of Anticancer Research2208-35452208-3553Bio-Byword Scientific Publishing Pty. Ltd.10.26689/par.v8i5.8323ArticleImmunoregulatory Effect and Mechanism of Epigallocatechin-3-Gallate in A Mouse Oral Cancer Modelhttps://artdesignp.com/journal/PAR/8/5/10.26689/par.v8i5.8323LiYizhen,HuangSiyi,LingYanzi,FuLiyan,ZhengRuyue,DuanXinwei,LuoYueji2024852024-09-26Objective: This investigation delineates the anti-cancer potency of epigallocatechin-3-gallate (EGCG) in an oral cancer mouse model, with a focus on its effect on T-cell activation. Methods: An oral cancer model was established in male Balb/c mice using 4-nitroquinoline 1-oxide (4-NQO). The mice were systematically grouped and administered graded concentrations of EGCG. Key parameters such as body weight, hydration levels, tumor volume, and mass were meticulously tracked. T-cell activity and cytokine expression profiles, focusing on interleukin-2 (IL-2), interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α), were quantified using ELISA. A comprehensive statistical evaluation included one-way ANOVA, Tukey’s HSD multiple comparison test, and the Kruskal-Wallis non-parametric assessment. Results: EGCG-administered cohorts exhibited a pronounced reduction in tumor size and mass, with the high-dose group showing the greatest efficacy. ELISA findings corroborated a significant increase in T-cell activity and concomitant upregulation of key cytokines, including IL-2, IFN-γ, and TNF-α (P < 0.05). Conclusion: This investigation confirms the tumor-suppressive efficacy of EGCG in a murine oral squamous cell carcinoma model. The therapeutic effects of EGCG are mediated through T-cell activation and the upregulation of pivotal cytokine expression, highlighting its potential immunomodulatory role in oral cancer treatment.

Sung H, Ferlay J, Siegel RL, et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 71(3): 209–249. https://doi.org/10.3322/caac.21660

Fang Y, Yu Y, Wu DW, et al., 2020, A Review of Immune-Related Adverse Events Associated with Immunotherapy. Zhonghua Zhong Liu Za Zhi, 42(1): 17–21. https://doi.org/10.3760/cma.j.issn.0253-3766.2020.01.002

Ferrari E, Bettuzzi S, Naponelli V, 2022, The Potential of Epigallocatechin Gallate (EGCG) in Targeting Autophagy for Cancer Treatment: A Narrative Review. Int J Mol Sci, 23(11): 6075. https://doi.org/10.3390/ijms23116075

Aggarwal V, Tuli HS, Tania M, et al., 2022, Molecular Mechanisms of Action of Epigallocatechin Gallate in Cancer: Recent Trends and Advancement. Semin Cancer Biol, 80: 256–275. https://doi.org/10.1016/j.semcancer.2020.05.011

Rawangkan A, Wongsirisin P, Namiki K, et al., 2018, Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth. Molecules, 23(8): 2071. https://doi.org/10.3390/molecules23082071

Xiao X, Jiang K, Xu Y, et al., 2019, (-)-Epigallocatechin-3-Gallate Induces Cell Apoptosis in Chronic Myeloid Leukaemia by Regulating Bcr/Abl-Mediated p38-MAPK/JNK and JAK2/STAT3/AKT Signalling Pathways. Clin Exp Pharmacol Physiol, 46(2): 126–136. https://doi.org/10.1111/1440-1681.13037

Huang SC, Kao YH, Shih SF, et al., 2021, Epigallocatechin-3-Gallate Exhibits Immunomodulatory Effects in Human Primary T Cells. Biochem Biophys Res Commun, 550: 70–76. https://doi.org/10.1016/j.bbrc.2021.02.132

Pan Y, Long X, Yi R, et al., 2018, Polyphenols in Liubao Tea Can Prevent CCl4-Induced Hepatic Damage in Mice through Its Antioxidant Capacities. Nutrients, 10(9): 1280. https://doi.org/10.3390/nu10091280

Shen H, Wu N, Liu Z, et al., 2017, Epigallocatechin-3-Gallate Alleviates Paraquat-Induced Acute Lung Injury and Inhibits Upregulation of Toll-Like Receptors. Life Sci, 170: 25–32. https://doi.org/10.1016/j.lfs.2016.11.021

Luo KW, Lung WY, Chun X, et al., 2018, EGCG Inhibited Bladder Cancer T24 and 5637 Cell Proliferation and Migration via PI3K/AKT Pathway. Oncotarget, 9(15): 12261–12272. https://doi.org/10.18632/oncotarget.24301

Zhou CG, Hui LM, Luo JM, 2018, Epigallocatechin Gallate Inhibits the Proliferation and Induces Apoptosis of Multiple Myeloma Cells via Inactivating EZH2. Eur Rev Med Pharmacol Sci, 22(7): 2093–2098. https://doi.org/10.26355/eurrev_201804_14742

Luo KW, Wei C, Lung WY, et al., 2017, EGCG Inhibited Bladder Cancer SW780 Cell Proliferation and Migration Both In Vitro and In Vivo via Down-Regulation of NF-KappaB and MMP-9. J Nutr Biochem, 41: 56–64. https://doi.org/10.1016/j.jnutbio.2016.12.004. Erratum in J Nutr Biochem, 123: 109530. https://doi.org/10.1016/j.jnutbio.2023.109530

Zhao J, Blayney A, Liu X, et al., 2021, EGCG Binds Intrinsically Disordered N-Terminal Domain of p53 and Disrupts p53-MDM2 Interaction. Nat Commun, 12(1): 986. https://doi.org/10.1038/s41467-021-21258-5